Avecia Biotechnology reaches contract with Pfizer to advertise Macugen Avecia Biotechnology, Inc., a respected provider of drug production and development providers for oligonucleotide therapeutics, has reached contract with Pfizer Inc.U generisk xenical . By Pfizer for the treating wet Age-Related Macular Degeneration. The contract with Pfizer to produce a key component of the commercial oligonucleotide-based therapeutic is normally testament to your experience, dependability and quality standards in regards to to technology transfer, procedure validation and the produce of oligonucleotide drug chemicals, says Detlef Rethage, President of Avecia Biotechnology, Inc..
Related StoriesApplying a high restaurant model to health care communications: an interview with Brandi Robinson, SanofiAddressing standard of living needs in prostate tumor: an interview with Professor Louis DenisGenetic carrier screening: an interview with Don Hardison, CEO of Great Start Genetics To accomplish renewed accreditation in the commission’s Healthcare Network Accreditation System, Availity submitted to a thorough independent evaluation of its adherence and business to the best level of industry standards and federal government rules. The commission evaluated Availity in regions of privacy procedures, systems availability, security infrastructure, and procedure for managing and transferring safeguarded health information.